細胞(bao)基(ji)因治(zhi)療是生物(wu)醫藥領域的(de)(de)前沿陣地(di),它通過對細胞(bao)或基(ji)因進行改造、修飾、調(diao)控,來糾正或補(bu)償因基(ji)因缺陷(xian)和異(yi)常(chang)引起的(de)(de)疾病(bing)(bing),為傳統(tong)療法(fa)難以攻克的(de)(de)疑(yi)難病(bing)(bing)癥,如遺傳性疾病(bing)(bing)、某(mou)些癌癥、自(zi)身免疫性疾病(bing)(bing)等,帶來了新(xin)的(de)(de)治(zhi)愈(yu)希望。
干(gan)細(xi)胞(bao)(bao)療(liao)(liao)法是細(xi)胞(bao)(bao)基(ji)因治療(liao)(liao)的重要分支。干(gan)細(xi)胞(bao)(bao)具備(bei)自(zi)我更新(xin)和多(duo)向分化潛(qian)能(neng),能(neng)分化成多(duo)種(zhong)功(gong)能(neng)細(xi)胞(bao)(bao),修復受損組(zu)織和器官。間(jian)充質干(gan)細(xi)胞(bao)(bao)(MSC)是其中備(bei)受關(guan)注(zhu)的類(lei)型(xing),具有免疫調(diao)節、抗炎、促(cu)進組(zu)織修復等(deng)特性。在臨(lin)床應用(yong)(yong)中,MSC 已被嘗試用(yong)(yong)于治療(liao)(liao)多(duo)種(zhong)疾(ji)病(bing),如移(yi)植(zhi)物抗宿主病(bing)、骨關(guan)節炎、心肌梗死等(deng),通過(guo)調(diao)節免疫微環境、促(cu)進組(zu)織再(zai)生等(deng)機制(zhi)發揮治療(liao)(liao)作用(yong)(yong)。
誘(you)導多(duo)能干細(xi)胞(bao)(bao)(bao)(iPSC)細(xi)胞(bao)(bao)(bao)療法是另(ling)一項創新(xin)性突破。iPSC 由成(cheng)體細(xi)胞(bao)(bao)(bao)經重編程(cheng)獲(huo)得,擁有類似胚(pei)胎(tai)干細(xi)胞(bao)(bao)(bao)的(de)多(duo)能性。它克服(fu)了胚(pei)胎(tai)干細(xi)胞(bao)(bao)(bao)來源的(de)倫理問題,可根據患者自身細(xi)胞(bao)(bao)(bao)定制,降(jiang)低免疫排斥風險。iPSC 能分(fen)化為各類細(xi)胞(bao)(bao)(bao),用于疾(ji)病建模、藥物篩選以及細(xi)胞(bao)(bao)(bao)移(yi)植(zhi)治療,為帕(pa)金森病、糖尿病等疾(ji)病的(de)治療帶來新(xin)曙光(guang)。
基(ji)因(yin)(yin)遞(di)(di)送(song)(song)(song)技(ji)術(shu)則是細(xi)胞(bao)基(ji)因(yin)(yin)治療(liao)的關(guan)鍵(jian)支撐。它負責將治療(liao)性基(ji)因(yin)(yin)安全、效(xiao)率高地遞(di)(di)送(song)(song)(song)至(zhi)靶細(xi)胞(bao)。轉染試劑是基(ji)因(yin)(yin)遞(di)(di)送(song)(song)(song)常用工具之一,通過特定機制將外(wai)源基(ji)因(yin)(yin)導(dao)入(ru)細(xi)胞(bao)。基(ji)因(yin)(yin)遞(di)(di)送(song)(song)(song)技(ji)術(shu)面臨(lin)遞(di)(di)送(song)(song)(song)效(xiao)率、靶向性、安全性等挑戰,理(li)想的遞(di)(di)送(song)(song)(song)系統需準確地將基(ji)因(yin)(yin)遞(di)(di)送(song)(song)(song)至(zhi)病變(bian)細(xi)胞(bao),避免脫(tuo)靶效(xiao)應,同(tong)時(shi)不(bu)引發免疫反應和(he)毒性。病毒載(zai)(zai)體(如腺(xian)相關(guan)病毒載(zai)(zai)體)和(he)非病毒載(zai)(zai)體(如脂質(zhi)納米顆粒)是目前(qian)主流(liu)的基(ji)因(yin)(yin)遞(di)(di)送(song)(song)(song)載(zai)(zai)體,科研人員不(bu)斷優(you)化載(zai)(zai)體設計,以提升(sheng)基(ji)因(yin)(yin)治療(liao)的有效(xiao)性和(he)安全性。
細胞(bao)基(ji)因治(zhi)療(liao)憑借干細胞(bao)療(liao)法(fa)、iPSC 細胞(bao)療(liao)法(fa)和基(ji)因遞送技術等(deng)不斷發展(zhan),有望為更多難治(zhi)性疾病提供治(zhi)愈(yu)方案,變革未來(lai)醫學格局。